Tubulin polymerization-IN-37 is a potent inhibitor (IC50: 2.3 μΜ) of tubulin polymerization by binding specifically to the colchicine site of tubulin and preventing colchicine binding. It has potential applications in cancer research, notably for lymphomas [1].

Tubulin polymerization-IN-37 (also referred to as compound 2f), at a concentration of 1 μM for 72 hours, significantly reduces the proliferation of lymphoma cells by over 50%. At concentrations of 50 and 500 nM over 24 to 72 hours, this compound induces apoptosis and arrests VL51 and MINO cells in the G2/M phase of the cell cycle. Furthermore, at a concentration of 5 μM, it inhibits the binding of colchicine to tubulin by 80%, demonstrating its mechanism of action. Tubulin polymerization-IN-37 also exhibits cytotoxic effects against MCF-7 cells with an IC50 value of 0.21 μM. Additionally, in a cell proliferation assay involving VL51, MINO, HBL1, and SU-DHL-10 cell lines treated with 0-10 μM of the compound for 72 hours, cell proliferation was inhibited to 28.1%, 8.6%, 7.3%, and 13.8% at 1 μM, respectively, with IC50 values of 0.12, 0.07, 0.08, and 0.07 μM respectively. Cell cycle analysis further confirmed the compound's effectiveness in arresting VL51 and MINO cells in the G2/M phase at concentrations of 50 and 500 nM after 24, 48, and 72 hours of treatment.